Catalog No.
Product Name
Application
Product Information
Citations
-
Tosufloxacin Derivative
A-71497 is a tosufloxacin derivative that serves as a prodrug, generating elevated plasma levels of tosufloxacin following both oral and subcutaneous administration in murine models. This compound is primarily utilized in antibiotic research to explore its pharmacokinetics and therapeutic efficacy. Its ability to enhance bioavailability makes it a valuable tool for studying antibiotic treatment strategies in preclinical settings. -
Anti-oxidant, Lipid Peroxidation/5-lipoxygenase Inhibitor
LY221068 is a potent inhibitor of iron-dependent lipid peroxidation and 5-lipoxygenase, exhibiting notable antioxidant properties. This compound demonstrates significant anti-inflammatory activity, particularly in preclinical models of arthritis, such as the Freund's Complete Adjuvant-induced arthritis model in rats, where it effectively reduces bone damage and paw swelling. LY221068 serves as a valuable tool for investigating inflammatory processes and potential therapeutic approaches in arthritis research. -
Gatifloxacin Derivative
3-Desmethyl Gatifloxacin is a derivative of Gatifloxacin that primarily targets bacterial DNA gyrase, inducing DNA cleavage. This compound is particularly useful in the study of gatifloxacin resistance, including in Quinolone-resistant mutants, making it a valuable tool for research on mechanisms of drug resistance in bacterial pathogens. -
LOX Inhibitor
SNT-5382 is a potent lysyl oxidase (LOX) inhibitor, designed to disrupt the enzymatic activity of LOX, which plays a critical role in extracellular matrix remodeling. This compound demonstrates significant biological activity in inhibiting tumor progression and metastasis, making it a valuable tool for cancer research. SNT-5382 can be utilized in various studies aimed at understanding the implications of LOX in malignancies and assessing potential therapeutic strategies. -
Lipoxygenase Inhibitor
Umbelliprenin is a prenylated coumarin that functions as a lipoxygenase inhibitor. It exhibits significant antioxidant properties along with anticancer, anti-inflammatory, and immunomodulatory activities. This compound effectively suppresses nitric oxide production in inflammatory macrophages, as well as inhibiting the expression of inducible nitric oxide synthase (iNOS). Umbelliprenin holds promise for research applications in the fields of inflammation, cancer biology, and immunology. -
5-LO/mPGES-1 Inhibitor
5-LO/mPGES1-IN-1 is a dual inhibitor of 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1), exhibiting IC50 values of 0.3 μM and 0.4 μM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research in inflammatory pathways. Applications include studies focused on the modulation of inflammatory responses, providing insights into potential therapeutic strategies for related diseases. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-2 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). This benzothiophen-2-yl pyrazole carboxylic acid derivative demonstrates significant analgesic and anti-inflammatory properties, exhibiting COX-2 inhibitory activity with an IC50 of 0.01 μM and 5-LOX inhibitory activity with an IC50 of 1.78 μM. COX-2/5-LOX-IN-2 is a valuable tool for research applications aimed at understanding and modulating inflammatory pathways. -
CO/5-LO Inhibitor
P-8977 is a potent dual inhibitor of cyclooxygenase (CO) and 5-lipoxygenase (5-LO) with an IC50 of 0.01 µM and 0.53 µM, respectively. This compound exhibits significant anti-inflammatory activity, demonstrated by its ability to reduce ear edema. P-8977 is valuable for research focused on inflammatory skin conditions and their underlying biochemical mechanisms. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
Lipoxygenase/COX Inhibitor
SKF-105809 is a dual inhibitor of lipoxygenase and cyclooxygenase (COX), targeting key enzymes involved in the inflammatory pathway. This compound demonstrates a significant reduction in edema and inflammatory cell infiltration in murine models of ear, paw, and peritoneal inflammation. Additionally, SKF-105809 reduces the production of acute-phase reactive proteins in models of arthritis and exhibits analgesic effects in abdominal contraction assays while preventing ulceration. Its applications extend to the study of inflammatory and immune system disorders, including peritonitis and arthritis. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-1 is a dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX), exhibiting IC50 values of 10.65 μM for COX-1, 0.075 μM for COX-2, and 2.98 μM for 15-LOX. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its ability to modulate key enzymes involved in arachidonic acid metabolism positions COX-2/15-LOX-IN-1 as a promising candidate for therapeutic investigation in inflammatory conditions. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), represented as a benzothiophen-2-yl pyrazole carboxylic acid derivative. This compound exhibits significant analgesic and anti-inflammatory properties, demonstrating enhanced efficacy compared to traditional nonsteroidal anti-inflammatory drugs. COX-2/5-LOX-IN-1 displays potent inhibition of COX-1, COX-2, and 5-LOX, with IC50 values of 12.13, 0.4, and 4.96 μM, respectively, making it a valuable tool for research in pain and inflammation pathways. -
COX-2/5-LOX Inhibitor
Speranskoside is a dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase-15 (5-LOX), exhibiting an IC50 of 2.62 μg/mL for COX-2 and 5.51 μg/mL for 5-LOX. This compound demonstrates significant anti-inflammatory activity, making it valuable for the investigation of gastric ulcers and related disorders. Its unique mechanism of action provides a foundational tool for research into inflammatory pathways and therapeutic interventions. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-3 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX), exhibiting IC50 values of 45.73 µM for COX-1, 5.45 µM for COX-2, and 4.33 µM for 5-LOX. This compound is valuable for studying inflammatory diseases, as it effectively modulates the associated biochemical pathways. Its dual inhibition may provide insights into the complex roles of COX-2 and 5-LOX in mediating inflammatory responses. -
Meloxicam Metabolite
5'-Hydroxy meloxicam is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) meloxicam, primarily involved in modulating cyclooxygenase (COX) enzyme activity. This compound exhibits anti-inflammatory properties and is essential for understanding the pharmacokinetics and metabolism of meloxicam in biological systems. Its study contributes to research on drug efficacy and safety profiles in chronic inflammatory conditions. -
5-lipoxygenase Inhibitor
L-651896 is a potent inhibitor of 5-lipoxygenase, exhibiting significant anti-inflammatory and antiproliferative properties. By obstructing the production of leukotrienes and prostaglandins, L-651896 is useful in investigating skin diseases and various other inflammatory conditions. Its mechanism of action supports research aimed at understanding the role of lipid mediators in inflammatory pathways. -
5-lipoxygenase/ cyclooxygenase Inhibitor
PD 127443 is an inhibitor of both 5-lipoxygenase and cyclooxygenase, targeting critical enzymes involved in the inflammatory response. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on understanding the mechanisms of inflammation and exploring potential therapeutic interventions in inflammatory diseases. -
COX/5-LOX Inhibitor
ZLJ-6 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), demonstrating potent oral bioactivity. With IC50 values of 0.73 μM for COX-1, 0.31 μM for COX-2, and 0.99 μM for 5-LOX, ZLJ-6 exhibits significant anti-inflammatory and analgesic properties. This compound is suitable for research applications aimed at investigating inflammatory pathways and potential therapeutic interventions. -
5-LOX/COX Inhibitor
(-)-Bornyl ferulate serves as a dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), displaying IC50 values of 10.4 μM and 12.0 μM, respectively. This compound demonstrates significant anti-inflammatory potential, making it useful for research focused on inflammation-related pathways and conditions. Its ability to modulate leukotriene and prostaglandin synthesis positions it as a valuable tool in the study of various inflammatory diseases and therapeutic interventions. -
12-Lipoxygenase Metabolite
12(S)-HPETE, a metabolite of 12-lipoxygenase, plays a crucial role in regulating vascular tone. It induces the expression of c-Fos and c-Jun proteins while increasing activating protein 1 (AP-1) activity in vascular smooth muscle cells. This compound may be pivotal in vasomotor regulation, influencing interactions between endothelial cells and adjacent blood cells. 12(S)-HPETE is useful for investigating cerebrovascular tension in various research contexts. -
COX/5-LOX Inhibitor
Phenethyl ferulate is a potent inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), displaying IC50 values of 4.35 μM and 5.75 μM, respectively. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways. Its ability to modulate these key enzymes positions it as a promising candidate for studies focused on inflammatory diseases and therapeutic interventions. -
5-LOX/COX Inhibitor
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions. -
5-LO/COX Inhibitor
BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) enzymes, exhibiting an IC50 of 5 μM for 5-LO. It also demonstrates inhibitory activity against COX-1 and COX-2, with IC50 values of 0.65 and 1.2 μg/mL, respectively. This compound is valuable for research applications involving inflammation and other related pathways. Its ability to concurrently inhibit key lipid mediators makes BW 755C a useful tool in studies focused on arachidonic acid metabolism and signaling pathways. -
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
5-LO/PGE2 Inhibitor
Canniprene is a potent inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase/microsomal prostaglandin E2 synthase (PGE2), with IC50 values of 0.4 μM and 10 μM, respectively. Derived from Cannabis sativa, Canniprene modifies the biosynthesis of inflammatory eicosanoids and prostaglandins, making it a valuable tool for researching inflammation and related pathways. Its unique mechanism of action positions Canniprene as a potential candidate for studying inflammatory diseases and therapeutic interventions targeting lipid mediators. -
TXA2/5-Lipoxygenase Inhibitor
CV-6504 is a dual inhibitor targeting thromboxane A2 (TXA2) synthase and 5-lipoxygenase. This compound demonstrates significant biological activity by scavenging reactive oxygen species (ROS) and exhibiting antitumor properties. CV-6504 is applicable in research focused on cancer, inflammation, and cardiovascular diseases, providing valuable insights into therapeutic strategies and molecular mechanisms. -
5-Lipoxygenase/Thromboxane Synthase Inhibitor
E 3040 is an orally active inhibitor of both 5-lipoxygenase and thromboxane synthase, key enzymes involved in inflammatory processes. This dual inhibition provides significant anti-inflammatory activity, making E 3040 a valuable reagent for research into inflammatory diseases and related pathways. Its unique mechanism can facilitate studies on the modulation of leukotrienes and thromboxanes in various biological contexts. -
5-LO/TXA2 Inhibitor
E-6700 is a potent inhibitor of 5-lipoxygenase (5-LO) and thromboxane A2 (TXA2) synthetase, with IC50 values of 16.3 μM and 0.026 μM, respectively. This compound effectively inhibits the production of leukotriene B4 (LTB4) and thromboxane B2 (TXB2). E-6700 is suitable for applications in anti-inflammatory research, providing a valuable tool for investigating pathways associated with inflammatory responses. -
5-LOX Inhibitor
5-O-Demethylnobiletin is an effective inhibitor of 5-lipoxygenase (5-LOX), exhibiting a potent IC50 of 0.1 μM without impacting COX-2 expression. This polymethoxyflavone, derived from Citrus jambhiri Lush., demonstrates notable anti-inflammatory properties by inhibiting leukotriene B4 (LTB4) production in rat neutrophils and elastase release in human neutrophils with an IC50 value of 0.35 μM. 5-O-Demethylnobiletin is valuable for research applications related to inflammation and leukotriene signaling pathways. -
5-LO Inhibitor
Enofelast (BI-L-239) is a selective inhibitor of 5-lipoxygenase (5-LO) with an IC50 of 2.48 μM, effectively blocking calcium ionophore-induced leukotriene B4 (LTB4) production. Its ability to modulate lipid mediators makes it a valuable tool for studying inflammatory pathways and leukotriene signaling in various biological contexts. Enofelast is suitable for research applications investigating the role of 5-LO in diseases associated with inflammation and immune response. -
PA2/5-LOX/COX Inhibitor
LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms. -
Cyclooxygenase/Lipoxygenase Inhibitor
L-652343 is a dual inhibitor of cyclooxygenase and lipoxygenase enzymes. It effectively inhibits the production of leukotriene B4 (LTB4) in isolated human polymorphonuclear leukocytes, demonstrating an IC50 value of 1.4 μM when challenged with Calcimycin. This compound is applicable in the study of inflammatory and immune diseases, providing insights into the mechanisms of these conditions and potential therapeutic interventions. -
5-LO Inhibitor
5-LOX-IN-6 is a potent and selective inhibitor of 5-lipoxygenase (5-LO), exhibiting reversible inhibition. It effectively reduces 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 µM and 0.086 µM, respectively. By inhibiting leukotriene biosynthesis, 5-LOX-IN-6 serves as a valuable tool in the study of inflammatory and allergic disorders. -
5-LOX Inhibitor
E 6080 is a specific inhibitor of 5-lipoxygenase (5-LOX), exhibiting an IC50 of 0.2 μM in rat basophilic leukemia cells. This compound effectively reduces leukotriene release, which is critical in the inflammatory response. E 6080 has demonstrated the ability to inhibit bronchospasm induced by antigen inhalation in sensitized guinea pigs, making it a valuable tool for asthma research and related inflammatory conditions. -
5-LOX Inhibitor
A63162 is a selective inhibitor of 5-lipoxygenase (5-LOX), a key enzyme in the biosynthesis of leukotrienes. This compound effectively inhibits both mitogen-induced proliferation of horse mononuclear cells and the synthesis of leukotriene LTB4 in response to Calcimycin at equivalent concentrations. A63162 is useful in research focused on chronic obstructive pulmonary disease, arthritis, and inflammatory bowel disease, offering insights into inflammatory pathways and potential therapeutic interventions. -
Moxifloxacin Metabolite
Moxifloxacin N-sulfate is a metabolite of the fluoroquinolone antibiotic moxifloxacin. This compound is primarily used in pharmacokinetic studies to better understand the metabolism and excretion of moxifloxacin in biological systems. Its analysis plays a crucial role in toxicology, safety assessment, and the evaluation of therapeutic efficacy in various research applications. -
Phenoloxidase Inhibitor
Phenylthiourea, a phenoloxidase inhibitor, effectively blocks the enzymatic oxidation of DOPA with a Ki value of 0.21 μM. This compound is recognized as a potent inhibitor of tyrosinase, making it valuable in research focused on melanin synthesis and pigmentation processes. Its use can result in observable physiological effects, such as the graying of hair in black rats, highlighting its impact on melanin formation. Phenylthiourea is essential for studies investigating the roles of phenoloxidase and tyrosinase in various biological systems. -
Levofloxacin Minor Metabolite
Levofloxacin N-oxide is a minor metabolite of the fluoroquinolone antibiotic Levofloxacin, primarily functioning as an antibacterial agent targeting DNA gyrase and topoisomerase IV. It demonstrates minimal genotoxic risks, which may provide insights into the safety profile of Levofloxacin. This compound is valuable for research applications focused on antibiotic metabolism and the mechanistic studies of bacterial resistance. -
Naloxegol Metabolite
N-Dealkylated-mPEG7-Naloxol is a metabolite of Naloxegol, functioning primarily as an opioid receptor antagonist. This compound is relevant for research involving opioid receptor modulation and can aid in investigating the pharmacokinetics and pharmacodynamics of Naloxegol. Its unique structural features make it suitable for applications in drug metabolism studies and the exploration of opioid receptor interactions. -
Raloxifene Oxidative Ddegradation
Raloxifene N-Oxide is an oxidative degradation product of Raloxifene, functioning primarily as a selective estrogen receptor modulator (SERM). This compound is of particular interest in research related to estrogen signaling pathways, as it may provide insights into the metabolism and pharmacokinetics of Raloxifene. Its biological activity allows for the exploration of estrogen receptor interactions and implications in conditions such as osteoporosis and breast cancer. -
Raloxifene Metabolite
Raloxifene Bismethyl Ether hydrochloride is a metabolic derivative of Raloxifene, characterized by the absence of both hydroxyl groups, rendering it inactive at the estrogen receptor. This compound serves as a valuable tool for studying the pharmacokinetics and metabolic pathways of Raloxifene in various biological systems. It is particularly useful in research focused on estrogen receptor signaling and related physiological processes. -
Raloxifene Metabolite
Raloxifene 6,4'-Bis-β-D-glucuronide is a metabolite of Raloxifene, functioning primarily as a selective estrogen receptor antagonist. This compound is significant in research related to osteoporosis prevention and estrogen receptor modulation. It serves as an important tool for studying the pharmacokinetics and biological effects of Raloxifene in various cellular contexts. -
5-lipoxygenase Inhibitor
ETH-615 is a potent inhibitor of 5-lipoxygenase, an enzyme involved in the biosynthesis of leukotrienes, which play a significant role in inflammatory processes. This compound demonstrates key biological activity in reducing inflammation and may have implications for research into cardiovascular diseases and other inflammatory disorders. Its efficacy in modulating leukotriene synthesis makes ETH-615 valuable for studies aimed at understanding the underlying mechanisms of cardiovascular pathology. -
15-LOX-1 Inhibitor
ML351 is a potent inhibitor of 15-lipoxygenase-1 (15-LOX-1) with an IC50 of 200 nM, demonstrating exceptional selectivity with over 250-fold preference compared to related isozymes such as 5-LOX, platelet 12-LOX, and 15-LOX-2, as well as ovine COX-1 and human COX-2. This compound has shown significant biological activity in preventing dysglycemia and reducing β-cell oxidative stress in a nonobese diabetic mouse model of Type 1 Diabetes. ML351 is useful in studying the role of 15-LOX-1 in metabolic diseases and may have implications for therapeutic strategies targeting oxidative stress in diabetes.
